Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan, 430030, People's Republic of China,
Curr Allergy Asthma Rep. 2014 Feb;14(2):415. doi: 10.1007/s11882-013-0415-3.
Inflammatory upper airway diseases, particularly chronic rhinosinusitis (CRS) and allergic rhinitis (AR), have a high worldwide prevalence. CRS and AR involve sustained and exaggerated inflammation that is associated with marked changes in gene and protein expression under tight regulation. A novel group of gene expression regulators is a class of short single-stranded RNA molecules termed microRNAs (miRNAs). miRNAs can cause gene silencing through degradation of target mRNAs or inhibition of translation. Dysregulated expression of miRNAs has been shown in various human diseases, such as cancer, inflammatory skin and bowel diseases, rheumatoid arthritis, and asthma. Although studies of miRNAs in inflammatory upper airway diseases are relatively new and few, emerging evidence implicates an involvement of miRNAs in shaping the inflammation pattern in upper airways. The purpose of this review is to provide an overview on our current understanding of miRNA expression and function in CRS and AR, and to underscore the potential for clinical usage of miRNAs in CRS and AR.
炎症性上呼吸道疾病,尤其是慢性鼻-鼻窦炎(CRS)和过敏性鼻炎(AR),在全球范围内具有较高的发病率。CRS 和 AR 涉及持续和过度的炎症,这种炎症与在严格调控下基因和蛋白表达的显著变化有关。一组新的基因表达调节剂是一类短的单链 RNA 分子,称为 microRNAs(miRNAs)。miRNAs 可以通过降解靶 mRNA 或抑制翻译来导致基因沉默。miRNAs 的表达失调已在多种人类疾病中得到证实,如癌症、炎症性皮肤和肠道疾病、类风湿关节炎和哮喘。尽管 miRNA 在炎症性上呼吸道疾病中的研究相对较新且数量较少,但新出现的证据表明 miRNA 参与了塑造上呼吸道炎症模式。本综述的目的是概述我们目前对 miRNA 在 CRS 和 AR 中的表达和功能的理解,并强调 miRNA 在 CRS 和 AR 中的临床应用潜力。